SEC Filing Summary: Innate Pharma S.A. (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Innate Pharma S.A., a foreign private issuer headquartered in Marseille, France, on October 26, 2021. The report covers the month of October 2021 and serves to disseminate a press release dated October 26, 2021 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The provided filing text contains only the cover page and signature block of the Form 6-K. It does not include the content of the referenced press release or any financial statements. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, liquidity, or other key financial metrics.
Material Changes
No material changes versus the prior comparable period can be identified from the provided text, as no financial data or operational updates are included in the excerpt.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or details regarding unusual items. These elements would be contained within the attached press release (Exhibit 99.1), which is not included in the input content.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K referencing a press release dated October 26, 2021, rather than a standalone financial report.
- Specific financial results and operational updates are not present in the provided text and must be sourced from the full press release (Exhibit 99.1).
- The report was signed by Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer.